Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disofenin
- Development stage
- Unknown
- Lead developer
- Sun Pharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Disofenin is an iminodiacetic acid (IDA) derivative that, when radiolabeled with technetium-99m (Tc-99m), serves as a diagnostic radiopharmaceutical for hepatobiliary imaging (cholescintigraphy). It is primarily indicated for the diagnosis of acute cholecystitis and the evaluation of hepatobiliary tract patency and function. Following intravenous administration, the Tc-99m disofenin complex is rapidly cleared from the bloodstream by hepatocytes via active transport mediated by organic anion-transporting polypeptides (OATPs), specifically OATP1B1 and OATP1B3. It is subsequently excreted unconjugated into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2), allowing for the visualization of the liver, gallbladder, and bile ducts.
- Brand names
- Hepatolite
- Other names
- 99mTc-DISIDA99mTc-disofeninDISIDAdisofenintechnetium (99mTc) disofenintechnetium Tc 99m disofenintechnetium Tc-99m disofenintechnetium-99m-diisopropyliminodiacetic acidtechnetium99m-diisopropyliminodiacetic acidtechnetium 99m-diisopropyliminodiacetic acid
02
Targets
ABCC2 (ATP-binding cassette sub-family C member 2)OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)
Beyond the preview
Go deeper on disofenin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disofenin.